Nasdaq:FATE
FATE THERAPEUTICS INC
A clinical-stage biopharmaceutical firm developing next-generation therapies for autoimmune diseases with a focus on gut-immune axis modulation.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe the company's novel gut-immune axis technology will achieve regulatory approval and secure lucrative licensing deals within the next two years. The strong cash position relative to current liabilities, combined with a diverse portfolio of marketable securities, offers a safety buffer against typical biotech volatility. If the clinical data for their lead candidates proves transformative for autoimmune patients, the current valuation could represent a significant upside opportunity upon successful commercialization.
Bear Case
The steep decline in revenue over the last three years and the massive retained earnings deficit suggest fundamental structural issues that may not be resolved quickly. The company is burning through cash at a rate of over $100M annually without any commercial product sales, creating an urgent need for equity dilution or strategic financing. Given the high probability of clinical trial attrition in this space and the lack of current profitability, the stock carries extreme downside risk for conservative investors.
About FATE THERAPEUTICS INC
Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for severe autoimmune diseases, particularly targeting the gut microbiome and immune system interactions. The company operates in the high-growth biotechnology sector with significant assets tied up in research and development for potential treatments addressing conditions like Crohn's disease and ulcerative colitis. Currently, the company relies heavily on external financing due to its early-stage clinical status and has not yet generated sufficient revenue to cover operating expenses.
Analysis
Management Discussion
Management has navigated a challenging environment where total revenue contracted sharply year-over-year, while operating expenses remained elevated with over $154M in total operating costs. Despite generating substantial interest income of $11.1M on its cash reserves, the company recorded a significant net loss of -$136.3M, reflecting the capital-intensive nature of advancing clinical candidates. The balance sheet remains robust with $208.7M in current assets against only $36.1M in current liabilities, suggesting sufficient liquidity to fund operations for the near term despite the widening deficit.
Industry Overview
The biopharmaceutical industry is characterized by long development cycles, high failure rates, and significant capital requirements before any revenue generation occurs. Companies in the autoimmune sector are actively seeking differentiated mechanisms of action to compete with established biologics that have saturated traditional markets. Regulatory pathways continue to evolve, offering potential accelerated approval options for therapies targeting unmet medical needs in severe autoimmune diseases.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $96.3M | $63.5M | $13.6M | $6.6M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $96.3M | $63.5M | $13.6M | $6.6M |
| Operating Expenses | $404.7M | $254.0M | $223.9M | $154.3M |
| Operating Income | $-308.4M | $-190.5M | $-210.3M | $-147.7M |
| R&D | $320.5M | $172.6M | $135.0M | $107.8M |
| G&A | $84.2M | $81.4M | $74.2M | $46.5M |
| Stock-Based Comp | $78.7M | $43.5M | $41.5M | $24.9M |
| D&A | $13.8M | $18.3M | $19.0M | $12.9M |
| Other OpEx | $0 | $0 | $14.7M | $0 |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Income | $5.8M | $17.2M | $17.3M | $11.1M |
| Pre-Tax Income | $-308.4M | $-190.5M | $-210.3M | $-147.7M |
| Income Tax | $0 | $0 | $0 | $2.0K |
| Continuing Ops | $-308.4M | $-190.5M | $-210.3M | $-147.7M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-281.7M | $-160.9M | $-186.3M | $-136.3M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-281.7M | $-160.9M | $-186.3M | $-136.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $502.1M | $331.5M | $291.9M | $208.7M |
| Cash & Equivalents | $61.3M | $41.9M | $36.1M | $46.6M |
| Marketable Securities | $374.9M | $273.3M | $243.0M | $157.0M |
| Accounts Receivable | $38.5M | $1.8M | $3.5M | $916.0K |
| Prepaid Expenses | $27.4M | $14.5M | $9.3M | $4.1M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $203.5M | $174.7M | $148.8M | $110.2M |
| PP&E (Net) | $110.0M | $96.8M | $64.4M | $56.9M |
| Operating Leases | $66.1M | $61.7M | $46.5M | $41.6M |
| LT Investments | $4.9M | $980.0K | $27.7M | $1.5M |
| Other LT Assets | $22.5M | $15.2M | $10.2M | $10.2M |
| Total Assets | $705.6M | $506.2M | $440.7M | $318.9M |
| Current Liabilities | $114.1M | $39.1M | $38.5M | $36.1M |
| Accounts Payable | $8.3M | $4.7M | $9.4M | $2.7M |
| Current Leases | $5.6M | $6.2M | $7.4M | $4.6M |
| Deferred Revenue | $42.2M | $685.0K | $393.0K | $381.0K |
| Other Current Liab | $4.0M | $0 | $0 | $8.4M |
| Long-Term Liabilities | $107.6M | $98.7M | $83.4M | $75.7M |
| LT Operating Leases | $103.7M | $97.4M | $77.8M | $73.3M |
| Other LT Liab | $3.9M | $1.3M | $5.6M | $2.4M |
| Total Liabilities | $221.6M | $137.8M | $122.0M | $111.8M |
| Shareholders' Equity | $483.9M | $368.4M | $318.7M | $207.2M |
| Paid-In Capital | $1.54B | $1.58B | $1.72B | $1.74B |
| Retained Earnings | $-1.05B | $-1.21B | $-1.40B | $-1.53B |
| AOCI | $-1.9M | $15.0K | $268.0K | $116.0K |
| Total L&E | $705.6M | $506.2M | $440.7M | $318.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-281.7M | $-160.9M | $-186.3M | $-136.3M |
| Non-Cash Adjustments | $-22.5M | $148.7M | $70.1M | $47.1M |
| Working Capital Changes | $56.0M | $-120.0M | $-6.7M | $-16.8M |
| Cash from Operations | $-248.2M | $-132.3M | $-122.9M | $-106.1M |
| Capital Expenditures | $35.6M | $6.2M | $730.0K | $6.0M |
| Cash from Investing | $166.8M | $112.7M | $12.2M | $111.2M |
| Cash from Financing | $9.2M | $85.0K | $99.9M | $5.5M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-72.2M | $-19.5M | $-10.8M | $10.6M |
| Beginning Cash | $148.8M | $76.6M | $57.0M | $46.3M |
| Ending Cash | $76.6M | $57.0M | $46.3M | $56.9M |
Frequently Asked Questions
How does FATE THERAPEUTICS INC make money?
The company's financial profile indicates a single primary revenue segment derived from grant funding, milestone payments, and licensing agreements rather than commercial product sales. Operating expenses are dominated by substantial research and development costs of $107.8M and general administrative expenses of $46.5M. The balance sheet shows minimal cost of revenue, consistent with a pre-revenue biotech entity where current assets like cash and marketable securities ($157.0M) are held for future clinical trials and potential commercialization.
What are the main risks for FATE?
The company faces a severe revenue decline trend, dropping from $96.3M in 2022 to just $6.6M in the latest reporting period, indicating potential issues with grant renewals or commercial partnerships. Significant cash burn is evident with net income of -$136.3M and operating cash flow of -$106.1M, raising concerns about liquidity sustainability given the massive retained earnings deficit of -$1.53B. Clinical trial failures are an inherent risk for clinical-stage companies that could render their substantial R&D investments worthless. The reliance on a single revenue stream makes the company vulnerable to changes in funding landscapes or regulatory approvals.
What is FATE's competitive advantage?
The company possesses proprietary intellectual property related to the gut-immune axis that differentiates its therapeutic approach from traditional biologics. Its substantial marketable securities holdings of $157.0M provide a financial runway to advance multiple clinical candidates without immediate pressure for profitability. The management team's focus on high-value, low-market-saturation autoimmune indications creates a potential first-mover advantage in an underserved patient population.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.